The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 28, 2014

Filed:

Feb. 20, 2009
Applicants:

Marit Otterlei, Trondheim, NO;

Per Arne Aas, Trondheim, NO;

Emadoldin Feyzi, Trondheim, NO;

Inventors:

Marit Otterlei, Trondheim, NO;

Per Arne Aas, Trondheim, NO;

Emadoldin Feyzi, Trondheim, NO;

Assignee:

Apim Therapeutics AS, Trondheim, NO;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/16 (2006.01); A61K 38/06 (2006.01); A61M 1/16 (2006.01); C07K 14/47 (2006.01); G01N 33/68 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/4738 (2013.01); C07K 2319/10 (2013.01); G01N 2800/56 (2013.01); G01N 33/6893 (2013.01); G01N 33/6872 (2013.01); A61K 38/00 (2013.01);
Abstract

The present invention provides an oligopeptidic compound comprising a PCNA interacting motif, or a nucleic acid molecule comprising a sequence encoding said oligopeptidic compound, for use in therapy, wherein the PCNA interacting motif is XXXXX- (SEQ ID NO: 1), wherein Xand X- are independently selected from the group of basic amino acids, Xis a lipophilic amino acid and Xand Xare independently selected from the group of uncharged amino acids; and wherein the oligopeptidic compound is further characterized by at least one of the following: (i) the oligopeptidic compound comprises at least one signal sequence; (ii) the PCNA interacting motif is [K/R]-F-[L/I/V]-[L/I/V]-[K/R] (SEQ ID NO: 27). Particularly the therapy may be the treatment of a disorder or condition where it is desirable to inhibit the growth of cells, for example a hyperproliferative disorder, or a treatment which involves cytostatic therapy e.g., myeloablation. In certain aspects the compounds of the invention may be used as cytostatic agents in their own right. In other aspects of the invention oligopeptidic compounds comprising such a motif may be used in conjunction with cytostatic agents or with radiotherapy.


Find Patent Forward Citations

Loading…